(4S,5R)-4-ISOBUTYL-5-PHENYLOXAZOLIDIN-2-ONE, 90.0%, 5g

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-isoleucine5g

Oxion Inverso OX.2053-PLPH-ICSI avec objectifs LWD Plan phase 10x/20x/40x, équipement ICSI et table croisée XY

1-Cyclohexyl-2,5-dimethyl-1H-pyrrole-3-carbaldehyde, 98%, 100mg

6-METHOXY-2-(TRIFLUOROMETHYL)-1,5-NAPHTHYRIDIN-4-OL, 95.0%, 1g

5-Chloro-2-mercaptobenzimidazole>98.0%(T)25g

Benzamide, N-[3-(dimethylamino)propyl]-4-(8-hydroxy-6-quinolinyl)-, 98%, 50mg

tert-Butyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate, 95.0%, 100mg

4-(chloromethyl)-1-methyl-1H-pyrazole hydrochloride, 95.0%, 5g

4-Methylsalicylic Acid>99.0%(GC)500g

3-(Bromomethyl)cyclobutane-1-carboxylic acid, 95+%, 1g

1-Boc-3-(3-Methyl-1,2,4-oxadiazol-5-yl)pyrrolidine, 95.0%, 1g

Methyl 4-amino-2-methoxy-5-nitrobenzoate, 95.0%, 250mg